Abattis Bioceuticals Corp (CSE: ATT) is to delist from the Canadian Securities Exchange. The reason behind the delisting is related to the company failing to comply with the regulations of the exchange.
Initially suspended from the Canadian Securities Exchange on February 6, 2019, the suspension was the result of Abatiis management failing to file year end financials within a 90 day time period. At the time, the company scheduled a conference call to inform investors of their current status on the matter, stating that the company expected to resume trading in a weeks time. The call however was subsequently postponed and never occurred.
in the time since, the company has replaced Chief Financial Officer Kent McParland, who was also a director on the board. While an acquisition was announced in April, the company has since failed to file the necessary documents to remove its suspension status.
Abattis Bioceuticals is expected to delist from the CSE at the close of trading on August 9, 2019.
Information for this analysis was found via Sedar, The CSE and Abattis Bioceuticals. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.